Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695500 versus Rituxan in first-line low tumor burden follicular lymphoma
2014-004544-36Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing BI 695500 with Rituxan (2 arms). Primary endpoint: Overall response rate at Week 30. Started Apr 2015; status: completed.
02
Drugs
MabionCD20rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2014-004544-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004544-36.